
|Videos|December 16, 2022
The Evolution of AR Pathway Inhibitors and Docetaxel Utilization in mCRPC Treatment and the Impact on Cabazitaxel
Author(s)Neal Shore, MD, FACS
Neal Shore, MD, FACS, speculates on how the utilization of AR-pathway inhibitors and docetaxel in earlier lines of mCRPC treatment has also influenced treatment with cabazitaxel.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
HHS requests testosterone therapy label updates, citing new safety data
2
Unmet needs and emerging solutions in MRI-guided prostate cancer care
3
Pearls & Perspectives: The Power of Advocacy in Sexual Medicine, With Rachel Rubin, MD
4
Microbial dysbiosis may predict response to CBM588 in mRCC
5












